Back to Search Start Over

Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights.

Authors :
Leo, Chen Huei
Ng, Hooi Hooi
Marshall, Sarah A.
Jelinic, Maria
Rupasinghe, Thusitha
Qin, Chengxue
Roessner, Ute
Ritchie, Rebecca H.
Tare, Marianne
Parry, Laura J.
Source :
British Journal of Pharmacology; Jan2020, Vol. 177 Issue 1, p217-233, 17p, 10 Graphs
Publication Year :
2020

Abstract

<bold>Background and Purpose: </bold>Endothelium-derived vasoconstriction is a hallmark of vascular dysfunction in hypertension. In some cases, an overproduction of endothelium-derived prostacyclin (PGI2 ) can cause contraction rather than relaxation. Relaxin is well known for its vasoprotective actions, but the possibility that this peptide could also reverse endothelium-derived vasoconstriction has never been investigated. We tested the hypothesis that short-term relaxin treatment mitigates endothelium-derived vasoconstriction in spontaneously hypertensive rats (SHR).<bold>Experimental Approach: </bold>Male Wistar Kyoto rats (WKY) and SHR were subcutaneously infused with either vehicle (20 mmol·L-1 sodium acetate) or relaxin (13.3 μg·kg-1 ·hr-1 ) using osmotic minipumps for 3 days. Vascular reactivity to the endothelium-dependent agonist ACh was assessed in vitro by wire myography. Quantitative PCR and LC-MS were used to identify changes in gene expression of prostanoid pathways and PG production, respectively.<bold>Key Results: </bold>Relaxin treatment ameliorated hypertension-induced endothelial dysfunction by increasing NO-dependent relaxation and reducing endothelium-dependent contraction. Notably, short-term relaxin treatment up-regulated mesenteric PGI2 receptor (IP) expression, permitting PGI2 -IP-mediated vasorelaxation. In the aorta, reversal of contraction was accompanied by suppression of the hypertension-induced increase in prostanoid-producing enzymes and reduction in PGI2 -evoked contractions.<bold>Conclusions and Implications: </bold>Relaxin has region-dependent vasoprotective actions in hypertension. Specifically, relaxin has distinct effects on endothelium-derived contracting factors and their associated vasoconstrictor pathways in mesenteric arteries and the aorta. Taken together, these observations reveal the potential of relaxin as a new therapeutic agent for vascular disorders that are associated with endothelium-derived vasoconstriction including hypertension. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00071188
Volume :
177
Issue :
1
Database :
Complementary Index
Journal :
British Journal of Pharmacology
Publication Type :
Academic Journal
Accession number :
141335783
Full Text :
https://doi.org/10.1111/bph.14858